Cargando…
P1021: JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE INTOLERANT TO RUXOLITINIB: AN OPEN-LABEL, SINGLE-ARM PHASE 2B STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431278/ http://dx.doi.org/10.1097/01.HS9.0000970984.18863.91 |
| _version_ | 1785091162648870912 |
|---|---|
| author | Zhang, Yi Zhou, Hu Xiao, Zhijian Duan, Minghui Gao, Sujun He, Guangsheng Jing, Hongmei LI, Junmin MA, Liangming Zhu, Huanling Chang, Chunkang Du, Xin Hong, Mei LI, Xin Liu, Qingchi Wang, Wei Na, Xu Yang, Haiping Zhao, Qingwei Jin, Jie |
| author_facet | Zhang, Yi Zhou, Hu Xiao, Zhijian Duan, Minghui Gao, Sujun He, Guangsheng Jing, Hongmei LI, Junmin MA, Liangming Zhu, Huanling Chang, Chunkang Du, Xin Hong, Mei LI, Xin Liu, Qingchi Wang, Wei Na, Xu Yang, Haiping Zhao, Qingwei Jin, Jie |
| author_sort | Zhang, Yi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431278 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104312782023-08-17 P1021: JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE INTOLERANT TO RUXOLITINIB: AN OPEN-LABEL, SINGLE-ARM PHASE 2B STUDY Zhang, Yi Zhou, Hu Xiao, Zhijian Duan, Minghui Gao, Sujun He, Guangsheng Jing, Hongmei LI, Junmin MA, Liangming Zhu, Huanling Chang, Chunkang Du, Xin Hong, Mei LI, Xin Liu, Qingchi Wang, Wei Na, Xu Yang, Haiping Zhao, Qingwei Jin, Jie Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431278/ http://dx.doi.org/10.1097/01.HS9.0000970984.18863.91 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Zhang, Yi Zhou, Hu Xiao, Zhijian Duan, Minghui Gao, Sujun He, Guangsheng Jing, Hongmei LI, Junmin MA, Liangming Zhu, Huanling Chang, Chunkang Du, Xin Hong, Mei LI, Xin Liu, Qingchi Wang, Wei Na, Xu Yang, Haiping Zhao, Qingwei Jin, Jie P1021: JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE INTOLERANT TO RUXOLITINIB: AN OPEN-LABEL, SINGLE-ARM PHASE 2B STUDY |
| title | P1021: JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE INTOLERANT TO RUXOLITINIB: AN OPEN-LABEL, SINGLE-ARM PHASE 2B STUDY |
| title_full | P1021: JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE INTOLERANT TO RUXOLITINIB: AN OPEN-LABEL, SINGLE-ARM PHASE 2B STUDY |
| title_fullStr | P1021: JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE INTOLERANT TO RUXOLITINIB: AN OPEN-LABEL, SINGLE-ARM PHASE 2B STUDY |
| title_full_unstemmed | P1021: JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE INTOLERANT TO RUXOLITINIB: AN OPEN-LABEL, SINGLE-ARM PHASE 2B STUDY |
| title_short | P1021: JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE INTOLERANT TO RUXOLITINIB: AN OPEN-LABEL, SINGLE-ARM PHASE 2B STUDY |
| title_sort | p1021: jaktinib in patients with myelofibrosis who were intolerant to ruxolitinib: an open-label, single-arm phase 2b study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431278/ http://dx.doi.org/10.1097/01.HS9.0000970984.18863.91 |
| work_keys_str_mv | AT zhangyi p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT zhouhu p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT xiaozhijian p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT duanminghui p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT gaosujun p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT heguangsheng p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT jinghongmei p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT lijunmin p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT maliangming p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT zhuhuanling p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT changchunkang p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT duxin p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT hongmei p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT lixin p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT liuqingchi p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT wangwei p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT naxu p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT yanghaiping p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT zhaoqingwei p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy AT jinjie p1021jaktinibinpatientswithmyelofibrosiswhowereintoleranttoruxolitinibanopenlabelsinglearmphase2bstudy |